Furthermore, approximately 10–20% of PDAC patients are known to harbor multiple KRAS mutation subtypes within a single PDAC mass, representing the presence of distinct tumor subclones and intratumoral heterogeneity.[9, 14] Thus, testing for the KRAS gene also reveals whether dPCR could accurately portray the intratumoral heterogeneity of a PDAC mass using only FNA biopsy specimens. Here, KRAS is linked to neoplasm.